Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcu Leqembi could open up access.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 27 October 2023, including: did Pfizer Inc. miss out on Roivant Sciences/Roche Holding AG deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi Sankyo Co., Ltd./Merck & Co., Inc. deal; Rybrevant at ESMO; and subcutaneous Leqembi could open up access.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Roivant/Roche: Did Pfizer Miss Out?" - Scrip, 23 Oct, 2023.)
(Also see "ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care" - Scrip, 23 Oct, 2023.)
(Also see "It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever" - Scrip, 23 Oct, 2023.)
(Also see "ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?" - Scrip, 23 Oct, 2023.)
(Also see "CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access" - Scrip, 25 Oct, 2023.)